Documentation Centre

 

 

  of 97 Next page

Go to page: of

Screenshot Date Categories Title Author Format
Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137:1132-1142. June 21, 2018 Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137:1132-1142. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, Frayha JC, et al. Key Publications
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. J Hypertens. 2018;36:916-923 June 14, 2018 The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. J Hypertens. 2018;36:916-923 Okin PM, Kjeldsen SE, Devereux RB Key Publications
Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A Randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538-546 May 31, 2018 Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A Randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538-546 Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S Key Publications
Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: The POUNDS lost trial. Diabetes Care. 2018;41:413-419 May 30, 2018 Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: The POUNDS lost trial. Diabetes Care. 2018;41:413-419 Heianza Y, Sun D, Smith SR, Bray GA, Sacks FM, Qi L Key Publications
Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11:e001696 May 30, 2018 Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11:e001696 Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group Key Publications
Therapeutic lowering of lipoprotein(a): A role for pharmacogenetics? Circ Genom Precis Med. 2018;11:e002052 May 30, 2018 Therapeutic lowering of lipoprotein(a): A role for pharmacogenetics? Circ Genom Precis Med. 2018;11:e002052 Boffa MB, Koschinsky M Key Publications
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541-551 May 10, 2018 Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541-551 Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S et al. Key Publications
Remission of type 2 diabetes: mission not impossible. Lancet. 2018;391:515-516 May 10, 2018 Remission of type 2 diabetes: mission not impossible. Lancet. 2018;391:515-516 Uusitupa M Key Publications
Comparison among criteria to define successful weight-loss maintainers and regainers in the Action for Health in Diabetes (Look AHEAD) and Diabetes Prevention Program trials. Am J Clin Nutr. 2017;106:1337-1346 April 30, 2018 Comparison among criteria to define successful weight-loss maintainers and regainers in the Action for Health in Diabetes (Look AHEAD) and Diabetes Prevention Program trials. Am J Clin Nutr. 2017;106:1337-1346 Berger SE, Huggins GS, McCaffery JM, Lichtenstein AH Key Publications
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319-328 April 27, 2018 Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319-328 Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group Key Publications

  of 97 Next page

Go to page: of